_version_ 1785090714244218880
author Buquicchio, Caterina
Salmanton-García, Jon
Marchesi, Francesco
Itri, Federico
Besson, Caroline
Martín-Pérez, Sonia
Dávila-Valls, Julio
Fianchi, Luana
Rahimli, Laman
Tarantini, Giuseppe
Grifoni, Federica Irene
Labrador, Jorge
Cordoba, Raul
Lopez-Garcia, Alberto
Fracchiolla, Nicola Stefano
Farina, Francesca
Cornely, Oliver A.
Pagano, Livio
author_facet Buquicchio, Caterina
Salmanton-García, Jon
Marchesi, Francesco
Itri, Federico
Besson, Caroline
Martín-Pérez, Sonia
Dávila-Valls, Julio
Fianchi, Luana
Rahimli, Laman
Tarantini, Giuseppe
Grifoni, Federica Irene
Labrador, Jorge
Cordoba, Raul
Lopez-Garcia, Alberto
Fracchiolla, Nicola Stefano
Farina, Francesca
Cornely, Oliver A.
Pagano, Livio
author_sort Buquicchio, Caterina
collection PubMed
description
format Online
Article
Text
id pubmed-10429442
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104294422023-08-17 PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY Buquicchio, Caterina Salmanton-García, Jon Marchesi, Francesco Itri, Federico Besson, Caroline Martín-Pérez, Sonia Dávila-Valls, Julio Fianchi, Luana Rahimli, Laman Tarantini, Giuseppe Grifoni, Federica Irene Labrador, Jorge Cordoba, Raul Lopez-Garcia, Alberto Fracchiolla, Nicola Stefano Farina, Francesca Cornely, Oliver A. Pagano, Livio Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429442/ http://dx.doi.org/10.1097/01.HS9.0000977036.45003.69 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Buquicchio, Caterina
Salmanton-García, Jon
Marchesi, Francesco
Itri, Federico
Besson, Caroline
Martín-Pérez, Sonia
Dávila-Valls, Julio
Fianchi, Luana
Rahimli, Laman
Tarantini, Giuseppe
Grifoni, Federica Irene
Labrador, Jorge
Cordoba, Raul
Lopez-Garcia, Alberto
Fracchiolla, Nicola Stefano
Farina, Francesca
Cornely, Oliver A.
Pagano, Livio
PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
title PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
title_full PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
title_fullStr PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
title_full_unstemmed PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
title_short PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
title_sort pb2586: passive preexposure immunization by tixagevimab/cilgavimab in covid 19 infected hematological malignancy of epicovidhea survey
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429442/
http://dx.doi.org/10.1097/01.HS9.0000977036.45003.69
work_keys_str_mv AT buquicchiocaterina pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT salmantongarciajon pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT marchesifrancesco pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT itrifederico pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT bessoncaroline pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT martinperezsonia pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT davilavallsjulio pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT fianchiluana pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT rahimlilaman pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT tarantinigiuseppe pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT grifonifedericairene pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT labradorjorge pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT cordobaraul pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT lopezgarciaalberto pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT fracchiollanicolastefano pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT farinafrancesca pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT cornelyolivera pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey
AT paganolivio pb2586passivepreexposureimmunizationbytixagevimabcilgavimabincovid19infectedhematologicalmalignancyofepicovidheasurvey